U.S. Androgenetic Alopecia Market Size & Outlook, 2024-2030
Global Market
Related Markets
U.S. androgenetic alopecia market highlights
- The U.S. androgenetic alopecia market generated a revenue of USD 926.3 million in 2023 and is expected to reach USD 1,426.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6.4% from 2024 to 2030.
- In terms of segment, pharmaceuticals was the largest revenue generating treatment in 2023.
- Devices is the most lucrative treatment segment registering the fastest growth during the forecast period.
Androgenetic alopecia market data book summary
| Market revenue in 2023 | USD 926.3 million |
| Market revenue in 2030 | USD 1,426.4 million |
| Growth rate | 6.4% (CAGR from 2023 to 2030) |
| Largest segment | Pharmaceuticals |
| Fastest growing segment | Devices |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pharmaceuticals, Devices |
| Key market players worldwide | Johnson & Johnson, Cipla Ltd DR, Sun Pharmaceutical Industries, Merck & Co Inc, Dr. Reddy’s Laboratories, Cardiff Lexington Corp, Amgen Inc, Theradome, Aurobindo Pharma, Curallux, Apira Science |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.1% of the global androgenetic alopecia market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. androgenetic alopecia market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 172.2 million by 2030.
The U.S. held the largest share of the androgenetic alopecia market in North America in 2023. The increasing awareness about the disease, rising R&D for novel therapeutics, and growing prevalence of androgenetic alopecia are some of the key factors propelling market growth.
According to the American Osteopathic College of Dermatology, AGA is the most common form of hair loss. It affects around 50% of males and 25% of females by the age of 50. Similarly, according to the Journal of Dermatology and Skin Scienceestimate, AGA affects around 50 million men and 30 million women in the U.S.
The positive phase 3 clinical trial results of potential drug candidates and the expected launch of pipeline products are expected to fuel market growth over the forecast period. For instance, in July 2023, Cosmo Pharmaceuticals started phase 3 clinical trials for its topical androgen receptorblocking drug, clascoterone solution.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Androgenetic Alopecia Market Scope
Androgenetic Alopecia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Cipla Ltd DR | View profile | 38,955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | www.cipla.com |
| Aurobindo Pharma | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | aurobindo.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | www.sunpharma.com |
| Dr. Reddy’s Laboratories | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | www.drreddys.com/ |
| Cardiff Lexington Corp | View profile | 13 | 3753 Howard Hughes Parkway, Suite 200, Las Vegas, NV, United States, 89169 | www.cardifflexington.com |
| Theradome | View profile | 1-10 | Pleasanton, California, United States, North America | www.theradome.com/ |
| Curallux | View profile | 101-250 | Miami, Florida, United States, North America | curallux.com/ |
U.S. Androgenetic Alopecia Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Androgenetic Alopecia Market Outlook will help companies and investors design strategic landscapes.
Pharmaceuticals was the largest segment with a revenue share of 98.25% in 2023.
Horizon Databook has segmented the U.S. androgenetic alopecia market based on pharmaceuticals, devices covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. held the largest share of the androgenetic alopecia market in North America in 2023. The increasing awareness about the disease, rising R&D for novel therapeutics, and growing prevalence of androgenetic alopecia are some of the key factors propelling market growth.
According to the American Osteopathic College of Dermatology, AGA is the most common form of hair loss. It affects around 50% of males and 25% of females by the age of 50. Similarly, according to the Journal of Dermatology and Skin Scienceestimate, AGA affects around 50 million men and 30 million women in the U.S.
The positive phase 3 clinical trial results of potential drug candidates and the expected launch of pipeline products are expected to fuel market growth over the forecast period. For instance, in July 2023, Cosmo Pharmaceuticals started phase 3 clinical trials for its topical androgen receptorblocking drug, clascoterone solution.
- U.S. Androgenetic Alopecia Market Treatment Outlook (Revenue, USD MIllion , 2018-2030)
- Pharmaceuticals
- Devices
- U.S. Androgenetic Alopecia Market End-use Outlook (Revenue, USD MIllion , 2018-2030)
- Homecare Settings
- Dermatology Clinics
- U.S. Androgenetic Alopecia Market Sales Channel Outlook (Revenue, USD MIllion , 2018-2030)
- Prescriptions
- OTC
- U.S. Androgenetic Alopecia Market Gender Outlook (Revenue, USD MIllion , 2018-2030)
- Male
- Female
Reasons to subscribe to Androgenetic Alopecia Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Androgenetic Alopecia Market Outlook databook
- Our clientele includes a mix of Androgenetic Alopecia Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Androgenetic Alopecia Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Androgenetic Alopecia Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.S. Androgenetic Alopecia Market, 2018-2030 (US$M)
U.S. androgenetic alopecia market statistics, by treatment, 2018-2030 (US$M)
